contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nanologica-receives-order-for-nlab-sagar-worth-approx-sek-37-million-from-returning-customer-in-china

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Nanologica is a life science tools company that develops, manufactures and sells advanced consumables to pharmaceutical companies. Nanologica's silica-based products are specially designed for the purification of peptide drugs, such as insulin and GLP-1 analogs. Nanologica operates in a global niche market for medicines for the treatment of diabetes and obesity. Nanologica was founded in 2004 and has its headquarters in Södertälje.

Nanologica

Nanologica has received an order for the company's silica-based purification media NLAB Saga® from a customer in China. The order is the second order placed by this customer and the value of...

<div class="mfn-preamble"><p><strong>Nanologica has received an order for the company's silica-based purification media NLAB Saga® from a customer in China. The order is the second order placed by this customer and the value of the new order amounts to approximately SEK 3.7 million.</strong></p></div><div class="mfn-body"><p>The customer is a pharmaceutical manufacturer that in June this year placed a first order for NLAB Saga® for production, after a period of evaluation of the product. Today's order is thus the second order for NLAB Saga® from the customer, who primarily produces peptides including GLP-1 analogues.<br>&nbsp;<br>“<em>It is very pleasing that we are now taking a recurring order for NLAB Saga® from a customer. It confirms that the product works and is seen as a competitive alternative to our competitors' products</em>”, Nanologica’s CEO Andreas Bhagwani comments.<br>&nbsp;<br><em>”Since the beginning of the year, we have been selling NLAB Saga®, i.e. silica for preparative chromatography, directly to end customers in China after we renegotiated the agreement with our distributor in China. This has been beneficial for us as we have been able to set up a dedicated team from Nanologica for sales of preparative silica in China, and we have a lower cost for our sales. The order we have now received is a result of the work that the team has done at the beginning of the year, and we look forward to the continued development in the Chinese market”,</em> CEO Andreas Bhagwani continues.</p></div><div class="mfn-footer mfn-contacts mfn-31afac252a6d"><p><strong class="mfn-heading-1">For further information, please contact</strong><br>Johanna Johansson<br>Director IR, Communications and Marketing<br>johanna.johansson@nanologica.com<br>+46 72 211 21 90</p></div><div class="mfn-footer mfn-about mfn-c09c1d849689"><p><strong class="mfn-heading-1">About Nanologica AB (publ)</strong><br>Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit <a rel="noopener" href="http://www.nanologica.com">www.nanologica.com</a>.</p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-09-26 09:52 CEST.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong><br><a rel="noopener" href="https://storage.mfn.se/cc92bf15-99d3-4064-af84-cbd932d858d9/nanologica-receives-order-for-nlab-saga-r-worth-approx-sek-3-7-million-from-returning-customer-in-china.pdf" class="mfn-generated mfn-primary">Nanologica Receives Order for NLAB Saga® Worth approx. SEK 3,7 Million from Returning Customer in China</a></p></div>

Nanologica Receives Order for NLAB Saga® Worth approx. SEK 3,7 Million from Returning Customer in China

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Drug development investment: Value creation through M&As and licensing agreements

Valuation methods: Valuation multiples

Helsinki Stock Exchange is cheap

Stay up to date with our newsletter